vs

Side-by-side financial comparison of MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI) and ATRenew Inc. (RERE). Click either name above to swap in a different company.

MARAVAI LIFESCIENCES HOLDINGS, INC. is the larger business by last-quarter revenue ($49.9M vs $43.2M, roughly 1.2× ATRenew Inc.). ATRenew Inc. runs the higher net margin — 16.9% vs -71.6%, a 88.5% gap on every dollar of revenue.

Maravai LifeSciences Holdings is a global life sciences firm developing critical reagents, diagnostic products, and tech solutions to support biopharma research, drug development, clinical diagnostics, and cell/gene therapy manufacturing. It serves biotech, pharma, research bodies and labs worldwide across three core segments.

ATRenew Inc. operates a leading pre-owned consumer electronics transaction and servicing ecosystem primarily in China. Its core services include end-to-end device recycling, professional quality inspection, certified refurbishment, and resale of smartphones, laptops, tablets and other digital products, serving both individual consumers and enterprise clients across domestic and select Southeast Asian markets.

MRVI vs RERE — Head-to-Head

Bigger by revenue
MRVI
MRVI
1.2× larger
MRVI
$49.9M
$43.2M
RERE
Higher net margin
RERE
RERE
88.5% more per $
RERE
16.9%
-71.6%
MRVI

Income Statement — Q4 FY2025 vs Q1 FY2023

Metric
MRVI
MRVI
RERE
RERE
Revenue
$49.9M
$43.2M
Net Profit
$-35.7M
$7.3M
Gross Margin
25.8%
Operating Margin
-117.9%
Net Margin
-71.6%
16.9%
Revenue YoY
-11.8%
Net Profit YoY
-37.7%
EPS (diluted)
$-0.24

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
MRVI
MRVI
RERE
RERE
Q4 25
$49.9M
Q3 25
$41.6M
Q2 25
$47.4M
Q1 25
$46.9M
Q4 24
$56.6M
Q3 24
$69.0M
Q2 24
$69.4M
Q1 24
$64.2M
Net Profit
MRVI
MRVI
RERE
RERE
Q4 25
$-35.7M
Q3 25
$-25.6M
Q2 25
$-39.6M
Q1 25
$-29.9M
Q4 24
$-25.9M
Q3 24
$-97.1M
Q2 24
$-9.8M
Q1 24
$-12.1M
Gross Margin
MRVI
MRVI
RERE
RERE
Q4 25
25.8%
Q3 25
13.6%
Q2 25
16.4%
Q1 25
16.5%
Q4 24
34.3%
Q3 24
46.7%
Q2 24
44.4%
Q1 24
40.3%
Operating Margin
MRVI
MRVI
RERE
RERE
Q4 25
-117.9%
Q3 25
-98.6%
Q2 25
-139.8%
Q1 25
-104.9%
Q4 24
-66.7%
Q3 24
-239.9%
Q2 24
-19.4%
Q1 24
-29.4%
Net Margin
MRVI
MRVI
RERE
RERE
Q4 25
-71.6%
Q3 25
-61.4%
Q2 25
-83.5%
Q1 25
-63.9%
Q4 24
-45.8%
Q3 24
-140.6%
Q2 24
-14.1%
Q1 24
-18.8%
EPS (diluted)
MRVI
MRVI
RERE
RERE
Q4 25
$-0.24
Q3 25
$-0.18
Q2 25
$-0.27
Q1 25
$-0.21
Q4 24
$-0.21
Q3 24
$-0.68
Q2 24
$-0.07
Q1 24
$-0.09

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
MRVI
MRVI
RERE
RERE
Cash + ST InvestmentsLiquidity on hand
$216.9M
$228.0M
Total DebtLower is stronger
$291.8M
Stockholders' EquityBook value
$212.4M
$557.1M
Total Assets
$770.6M
$722.9M
Debt / EquityLower = less leverage
1.37×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
MRVI
MRVI
RERE
RERE
Q4 25
$216.9M
Q3 25
$243.6M
Q2 25
$269.9M
Q1 25
$285.1M
Q4 24
$322.4M
Q3 24
$578.2M
Q2 24
$573.2M
Q1 24
$561.7M
Total Debt
MRVI
MRVI
RERE
RERE
Q4 25
$291.8M
Q3 25
$292.8M
Q2 25
$293.9M
Q1 25
$294.9M
Q4 24
$295.9M
Q3 24
$521.7M
Q2 24
$522.5M
Q1 24
$523.3M
Stockholders' Equity
MRVI
MRVI
RERE
RERE
Q4 25
$212.4M
Q3 25
$245.4M
Q2 25
$265.9M
Q1 25
$300.6M
Q4 24
$325.3M
Q3 24
$344.9M
Q2 24
$434.7M
Q1 24
$410.7M
Total Assets
MRVI
MRVI
RERE
RERE
Q4 25
$770.6M
Q3 25
$849.2M
Q2 25
$897.0M
Q1 25
$959.8M
Q4 24
$1.0B
Q3 24
$1.3B
Q2 24
$1.4B
Q1 24
$1.4B
Debt / Equity
MRVI
MRVI
RERE
RERE
Q4 25
1.37×
Q3 25
1.19×
Q2 25
1.11×
Q1 25
0.98×
Q4 24
0.91×
Q3 24
1.51×
Q2 24
1.20×
Q1 24
1.27×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
MRVI
MRVI
RERE
RERE
Operating Cash FlowLast quarter
$-22.8M
Free Cash FlowOCF − Capex
$-24.9M
FCF MarginFCF / Revenue
-49.9%
Capex IntensityCapex / Revenue
4.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-70.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
MRVI
MRVI
RERE
RERE
Q4 25
$-22.8M
Q3 25
$-15.2M
Q2 25
$-10.3M
Q1 25
$-9.4M
Q4 24
$-14.6M
Q3 24
$13.1M
Q2 24
$17.4M
Q1 24
$-8.5M
Free Cash Flow
MRVI
MRVI
RERE
RERE
Q4 25
$-24.9M
Q3 25
$-18.1M
Q2 25
$-13.1M
Q1 25
$-14.6M
Q4 24
$-20.5M
Q3 24
$4.5M
Q2 24
$7.9M
Q1 24
$-14.1M
FCF Margin
MRVI
MRVI
RERE
RERE
Q4 25
-49.9%
Q3 25
-43.4%
Q2 25
-27.7%
Q1 25
-31.2%
Q4 24
-36.2%
Q3 24
6.6%
Q2 24
11.4%
Q1 24
-22.0%
Capex Intensity
MRVI
MRVI
RERE
RERE
Q4 25
4.2%
Q3 25
7.0%
Q2 25
6.1%
Q1 25
11.2%
Q4 24
10.3%
Q3 24
12.4%
Q2 24
13.8%
Q1 24
8.8%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

MRVI
MRVI

Cygnus Segment$27.2M54%
Other$18.4M37%
Shipping And Handling$4.3M9%

RERE
RERE

Segment breakdown not available.

Related Comparisons